Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche and Technoclone have entered a strategic alliance to co-develop a portfolio of coagulation assays.
Subscribe to our email newsletter
Technoclone is a reagent specialist in thrombosis and cardiovascular diagnostics.
The collaboration is believed to support Roche’s plans to develop a new line of analyzers for the central coagulation lab, which will be marketed under Roche’s cobas brand.
The new range, subject to regulatory approval is likely to be launched in the US and Canada in 2014.
Under the deal, Roche will also market Technoclone’s range of Research Use Only products that address the needs of specialists and researchers in the hemostasis research community.
Roche Diagnostics marketing vice president Randy Pritchard said Technoclone would bring industry expertise to this collaboration and both the companies share goals of bringing improved medical value to healthcare providers and patients.
"The expansion of the reagent menu into key areas of hemostasis will greatly enhance the new line of laboratory coagulation analyzers in development and will open up new opportunities for research related to targeted treatment and personalized healthcare," Pritchard added.